** Shares of drugmaker Abeona Therapeutics ABEO.O up 12.7% at $6.03 premarket
** ABEO says the U.S. FDA has approved its gene therapy for a rare skin disorder
** The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa
** The current standard-of-care treatment is daily wound care and protective bandaging
** Company says the treatment is expected to be available in Q3 2025
** As of last close, ABEO shares down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。